Close Menu

NEW YORK: Abcam has entered a global distribution agreement to sell Avacta's recently developed SARS-CoV-2 research ELISA Affimer reagents, Avacta said on Tuesday.

Under the non-exclusive distribution agreement, Cambridge, UK-based Abcam will sell Avacta’s SARS-CoV-2 spike protein Affimer research reagents.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.